ClinicalTrials.Veeva

Menu

Normal Values for Esophageal and Pyloric Impedance Planimetry Under General Anesthesia (NormaFLIP)

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Unknown

Conditions

Pylorus Dysfunction
Esophageal Dysfunction

Treatments

Device: EndoFLIP

Study type

Interventional

Funder types

Other

Identifiers

NCT02905669
69HCL16_0457

Details and patient eligibility

About

Impedance planimetry using Endoscopic Functional Lumen Imaging Probe (EndoFLIP) device is a promising diagnostic tool to assess esophageal, esophago-gastric junction and pylorus function. It allows the measurement of esophageal and pylorus distensibility as well as contractile activity in response to distension. Examination is useful performed under sedation. General anesthesia might affect distensibility values. The aim of this study is to normal values for esophageal, esophago-gastric junction and pylorus distensibility in controls during an upper gastro-intestinal endoscopy performed under general anesthesia.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject older than 18 years and younger than 80 years
  • Subject referred for upper gastro-intestinal endoscopy under general anesthesia for anemia, intestinal metaplasia in the stomach, Helicobacter pylori screening, or submucosal dissection
  • Subject with health insurance
  • Written informed consent

Exclusion criteria

  • Patient younger than 18 years or older than 80 years
  • Pregnancy or breast feeding
  • Previous history of esophago-gastric surgery or vagotomy
  • Previous history of Parkinson disease or diabetes mellitus
  • Contra-indication to upper gastro-intestinal endoscopy
  • Esophageal varices
  • Esophageal diameter smaller than 5 mm
  • Contra-indication to general anesthesia
  • Hiatal hernia greater than 3 cm on endoscopy
  • Esophageal or gastric cancer otherwise than superficial lesion with indication of submucosal dissection
  • Typical symptoms (heartburn, regurgitation) of gastro-esophageal reflux disease and/or gastroesophageal reflux disease (GERD)-Q score greater or equal to 8
  • Nausea, vomiting or epigastric pain
  • Dysphagia with Sydney score greater ou equal to 50
  • Incapability to give consent
  • No written informed consent
  • Participation to another study at the same time

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

40 participants in 1 patient group

EndoFLIP
Experimental group
Description:
Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device.
Treatment:
Device: EndoFLIP

Trial contacts and locations

1

Loading...

Central trial contact

Sabine ROMAN, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems